As we observed that tumor samples with low SMG1 expression were more abundant in exhausted CD8 lymphocytes (Fig. 1F-H) we decided to evaluate whether the inhibition of NMD could improve the outcome of anti-CTLA-4 and anti-PD-1 (ICB) therapy in 4T1 tumors. The gene discussed is CD8A; the disease is neoplasm.